Condition
WHO Grade 4 Glioma
Total Trials
5
Recruiting
3
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 1 (1)
P 2 (3)
Trial Status
Recruiting3
Active Not Recruiting1
Not Yet Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06964737Phase 1Recruiting
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
NCT07091864Not ApplicableRecruiting
Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma
NCT03919071Phase 2Active Not Recruiting
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
NCT07206849Phase 2Not Yet Recruiting
Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)
NCT06444412Phase 2Recruiting
An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With Glioma
Showing all 5 trials